<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072330</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-536TCH/CCT-001</org_study_id>
    <secondary_id>JapicCTI-121962</secondary_id>
    <nct_id>NCT02072330</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorothiazide Monotherapy in Patients With Grade I or II Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety of combined administration
      of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide
      (HCTZ) with those of TAK-536CCB in patients with Grade I or II essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, multicenter, phase 2/3 study to evaluate the
      efficacy and safety of combined administration of TAK-536CCB and Hydrochlorothiazide (HCTZ)
      with those of TAK-536CCB or Hydrochlorothiazide in patients with grade I or II essential
      hypertension.

      This study consists of a 4-week single-blind placebo run-in period and a 10-week double-blind
      treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the office trough sitting diastolic blood pressure (DBP)</measure>
    <time_frame>Baseline and Week 10</time_frame>
    <description>Change in the office trough sitting DBP from the end of the placebo run-in period (baseline [Week 0]) to the end of the treatment period (Week 10, last observation carried forward [LOCF])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the office trough sitting systolic blood pressure (SBP)</measure>
    <time_frame>Baseline and Week 10</time_frame>
    <description>Change in the office trough sitting SBP from the end of the placebo run-in period (baseline [Week 0]) to the end of the treatment period (Week 10, last observation carried forward [LOCF])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving &lt; 140/90 mmHg</measure>
    <time_frame>10 weeks</time_frame>
    <description>Patients achieving &lt; 140/90 mmHg refer to those meeting both of the following criteria:
A decrease to &lt; 90 mmHg in office trough sitting DBP
A decrease to &lt; 140 mmHg in office trough sitting SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders (140/90 mmHg criterion)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Patients who met either of the following conditions are regarded as responders (140/90 mmHg criterion).
A ≥ 20 mmHg decrease in office trough sitting SBP and a ≥ 10 mmHg decrease in the office trough sitting DBP
A decrease to &lt; 140 mmHg in office trough sitting SBP and a decrease to &lt; 90 mmHg in office trough sitting DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events( including vital sign, body weight, ECG findings and laboratory tests)</measure>
    <time_frame>10 weeks</time_frame>
    <description>The frequency of adverse events by type, seriousness. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time profile of office trough sitting diastolic blood pressure</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time profile of office trough sitting systolic blood pressure</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Grade I or II Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-536CCB</intervention_name>
    <description>TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets</description>
    <arm_group_label>TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)</arm_group_label>
    <other_name>Fix-dose combination of Azilsartan and Amlodipine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-536CCB + Hydrochlorothiazide</intervention_name>
    <description>TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets</description>
    <arm_group_label>TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)</arm_group_label>
    <other_name>Hydrochlorothiazide and fix-dose combination of Azilsartan and Amlodipine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets</description>
    <arm_group_label>Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2</description>
    <arm_group_label>Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-536CCB + Hydrochlorothiazide</intervention_name>
    <description>TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2</description>
    <arm_group_label>TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)</arm_group_label>
    <other_name>Hydrochlorothiazide and fix-dose combination of Azilsartan and Amlodipine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Grade I or II essential hypertension.

          2. An office sitting systolic blood pressure of ≥ 150 and &lt; 180 mmHg, and an office
             sitting diastolic blood pressure of ≥ 95 and &lt; 110 mmHg during the placebo run-in
             period at Week −2 and Week 0.

          3. Male or female aged 20 years or older at the time of providing informed consent.

          4. Outpatient.

        Exclusion Criteria:

          1. Secondary hypertension, grade III hypertension or malignant hypertension.

          2. An office sitting systolic blood pressure of ≥160 mmHg or sitting diastolic blood
             pressure of ≥100 mmHg recorded while on combined therapy with 3 or more
             antihypertensives within 4 weeks prior to the initiation of the placebo run-in period
             and at Week −4.

        3 Evident white coat hypertension or white coat phenomenon. 4. Day-night reversed
        lifestyle, such as night-time workers. 5. Sleep apnea syndrome requiring treatment. 6. Have
        any of the cardiovascular disease or symptoms listed below:

          -  Heart disease: myocardial infarction (within 24 weeks before the placebo run-in
             period), coronary arterial revascularization (within 24 weeks before the placebo
             run-in period), severe valvular disease, atrial fibrillation, or following diseases
             which require medication: angina pectoris, congested heart failure, or arrhythmia.

          -  Cerebrovascular disease: cerebral infarction, cerebral hemorrhage (within 24 weeks
             before the placebo run-in period), or transient ischemic attack (within 24 weeks
             before the placebo run-in period).

          -  Vascular diseases: peripheral arterial disease with intermittent claudication, artery
             dissection, aneurysm

          -  Advanced hypertensive retinopathy: bleeding, exudation, or papilledema (within 24
             weeks before the placebo run-in period).

             7. Clinically significant hepatic disorder. 8. Clinically significant renal
             impairment. 9. Significantly low or high Potassium or Sodium levels. 10. Complicated
             by gout, or had a past history of gout within 24 weeks prior to the initiation of the
             placebo run-in period, or complicated by hyperuricemia requiring medication.

             11. Diabetic subject on insulin treatment or poorly controlled type 2 diabetes
             mellitus.

             12. Have a malignant tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Touon-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanamaki-shi</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama-shi</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension, Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

